Myriad Genetics (NASDAQ:MYGN) and Heska (NASDAQ:HSKA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.
Insider & Institutional Ownership
96.7% of Myriad Genetics shares are owned by institutional investors. Comparatively, 96.1% of Heska shares are owned by institutional investors. 2.8% of Myriad Genetics shares are owned by company insiders. Comparatively, 11.7% of Heska shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent recommendations for Myriad Genetics and Heska, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Myriad Genetics | 3 | 3 | 0 | 0 | 1.50 |
Heska | 0 | 1 | 4 | 0 | 2.80 |
Myriad Genetics currently has a consensus price target of $17.20, suggesting a potential downside of 38.22%. Heska has a consensus price target of $185.80, suggesting a potential upside of 8.22%. Given Heska's stronger consensus rating and higher possible upside, analysts plainly believe Heska is more favorable than Myriad Genetics.
Earnings and Valuation
This table compares Myriad Genetics and Heska's revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Myriad Genetics | $638.60 million | 3.28 | $-199,500,000.00 | ($0.35) | -79.54 |
Heska | $122.66 million | 13.26 | $-1,470,000.00 | $0.05 | 3,433.60 |
Heska has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Myriad Genetics has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, Heska has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.
Profitability
This table compares Myriad Genetics and Heska's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Myriad Genetics | -32.49% | -4.07% | -2.68% |
Heska | -11.15% | -2.29% | -1.64% |
Summary
Heska beats Myriad Genetics on 10 of the 14 factors compared between the two stocks.